Class ITerminatedD-1350-2022
Drug recall · August 10, 2022
SUSTANGO recall
Why: Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.
- Lots / codes
Lot DAP272109, Exp: 4/1/2026
- Quantity
- 750 cartons
- Company
- Ultra Supplement LLC, Wilmington, DE
- Distribution
- Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.
- Initiated
- July 21, 2022 · Voluntary: Firm initiated
- Classified
- August 17, 2022
- Reported
- August 10, 2022
- Ended
- October 16, 2023
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.